Novartis Skin Treatment Drug Cosentyx Gets US FDA Approval
01 Noviembre 2023 - 12:43AM
Noticias Dow Jones
By Pierre Bertrand
Novartis said the U.S. Food and Drug Administration has approved
its drug Cosentyx for the treatment of the hidradenitis suppurativa
skin condition.
Novartis said late Tuesday that the approval of the drug is the
first of a new biologic treatment option for the condition in
nearly a decade.
The regulator's approval was based on data compiled in the
Sunshine and Sunrise Phase 3 study program, Novartis said.
Hidradenitis suppurativa is a chronic and systemic skin disease
which causes boil-like bumps that can burst and cause scarring, the
company said.
Novartis said there has previously only been one other treatment
option for the condition.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
November 01, 2023 02:28 ET (06:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De May 2023 a May 2024
